“Early” initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease

No abstract is available for this paper.

• Publication year

  1991

• Venue

  Neurology

• Publication date

  1991-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1212/WNL.41.5.622PMID 2027475
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra

  1991cited by this paper
• Early combination of selegiline and low-dose levodopa as initial symptomatic therapy in Parkinson's disease. Experience in 26 patients receiving combined therapy for 26 months.

  1991cited by this paper
• The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa

  1991cited by this paper
• Chronic levodopa treatment alters basal and dopamine agonist-stimulated cerebral glucose utilization

  1990cited by this paper
• L-deprenyl, levodopa pharmacokinetics, and response fluctuations in Parkinson's disease.

  1990cited by this paper
• Basic FGF reverses chemical and morphological deficits in the nigrostriatal system of MPTP-treated mice

  1990cited by this paper
• The promise and limitations of controlled-release oral levodopa administration.

  1989cited by this paper
• Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa.

  1989cited by this paper
• Cognitive impairments associated with early Parkinson's disease

  1989cited by this paper
• Deprenyl as symptomatic therapy in Parkinson's disease.

  1988cited by this paper
• Central mechanisms and levodopa response fluctuations in Parkinson's disease.

  1988cited by this paper
• Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, part II

  1988cited by this paper
• Does levodopa aggravate Parkinson's disease?

  1988cited by this paper
• Factors that influence the occurrence of response variations in Parkinson's disease

  1987cited by this paper
• Multi‐center study of Parkinson mortality with early versus later dopa treatment

  1987cited by this paper
• Long‐term follow‐up of early dopa treatment in Parkinson's disease

  1986cited by this paper
• Dementia in idiopathic Parkinson's disease

  1986cited by this paper
• Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients

  1986cited by this paper
• Result of chronic levodopa therapy and its modification by bromocriptine in Parkinson's disease

  1985cited by this paper
• Nigrostriatal Dopaminergic Neurons Remain Undamaged in Rats Given High Doses of l‐DOPA and Carbidopa Chronically

  1984cited by this paper
• How common is dementia in Parkinson's disease?

  1984cited by this paper
• Evidence to support early levodopa therapy in Parkinson disease

  1981cited by this paper
• Interaction of pergolide with central dopaminergic receptors.

  1980cited by this paper
• Intermittent versus continuous stimulation: effect of time interval on the development of sensitization or tolerance.

  1980cited by this paper
• Analysis of the clinical problems in parkinsonism and the complications of long‐term levodopa therapy

  1979cited by this paper
• Receptor basis for dopaminergic supersensitivity in Parkinson's disease

  1978cited by this paper
• Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity.

  1977cited by this paper
• DEMENTIA IN PARKINSON'S DISEASE

  1976cited by this paper
• Parkinsonism, L-dopa, and intelligence.

  1973cited by this paper
• Intellectual impairment in Parkinson's syndrome.

  1972cited by this paper
• The prevalence, natural history and dementia of Parkinson's disease.

  1966cited by this paper

• Omnidirectional leaky opto-electrical fiber for optogenetic control of neurons in cell replacement therapy.

  2022cites this paper
• Medical treatment of the motor features of Parkinson disease

  2021cites this paper
• K channel blockage with 3,4-diaminopyridine potentiates the effect of L-DOPA on dopamine release in striatal slices prepared from 6-OHDA pre-treated rats

  2020cites this paper
• Hallmarks of Clinical Aspects of Parkinson's Disease Through Centuries.

  2017cites this paper
• Effects of a combination treatment of KD5040 and L-dopa in a mouse model of Parkinson’s disease

  2017cites this paper
• Combined treatment with acupuncture reduces effective dose and alleviates adverse effect of L-dopa by normalizing Parkinson's disease-induced neurochemical imbalance.

  2014cites this paper
• Chinese culture permeation in the treatment of Parkinson disease: a cross-sectional study in four regions of China

  2014cites this paper
• The Costs and Benefits of Deep Brain Stimulation Surgery for Patients with Parkinson’s Disease at Different Stages of Severity – An Initial Exploration

  2013cites this paper
• PET studies in Parkinson's disease dyskinesias and dementia

  2012cites this paper
• Health-Related Quality of Life and Healthcare Utilisation in Patients with Parkinson’s Disease

  2012cites this paper
• L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?

  2011cites this paper
• Optimal time for beginning treatment with levodopa

  2010cites this paper
• [Optimal time for beginning treatment with levodopa].

  2010cites this paper
• Effects of early vs. late initiation of levodopa treatment in hemiparkinsonian rats

  2009cites this paper
• Levodopa therapeutics for Parkinson's disease: new developments.

  2009cites this paper
• Levodopa in the early treatment of Parkinson's disease.

  2009cites this paper
• Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.

  2009cites this paper
• Levodopa in the treatment of Parkinson’s disease

  2009cites this paper
• Treatment of Parkinson's disease.

  2009cites this paper
• Motor complications in Parkinson disease: clinical manifestations and management.

  2008cites this paper
• Chapter 6 – Medical treatment of Parkinson disease

  2007cites this paper
• Motor fluctuations and dyskinesias in advanced/end stage Parkinson’s disease: a study from a population of brain donors

  2007influential citation
• Levodopa in the treatment of Parkinson's disease.

  2006cites this paper
• Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990.

  2006cites this paper
• Idiopathic parkinsons disease: epidemiology, diagnosis and management

  2006cites this paper
• The structural evolution of dopamine D3 receptor ligands: structure-activity relationships and selected neuropharmacological aspects.

  2006cites this paper
• Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single‐dose challenges

  2005cites this paper
• Does levodopa slow or hasten the rate of progression of Parkinson’s disease?

  2005cites this paper
• Progress in Clinical Neurosciences: A Forum on the Early Management of Parkinson's Disease

  2005cites this paper
• Dopamine and Glutamate in Parkinson’s Disease

  2005cites this paper
• Involuntary Movements Caused By Levodopa

  2004cites this paper
• Motor Complications in Parkinson Disease:: A Prospective Follow-Up Study

  2004cites this paper
• Outcome measures for clinical trials in Parkinson’s disease: achievements and shortcomings

  2004cites this paper
• Pergolide Mesylate, a Dopaminergic Receptor Agonist, Applied With l-DOPA Enhances Serum Antioxidant Enzyme Activity in Parkinson Disease

  2004cites this paper
• Measuring motor complications in clinical trials for early Parkinson’s disease

  2003cites this paper
• Switching and combining dopamine agonists

  2003cites this paper
• Clinical Pharmacokinetic and Pharmacodynamic Properties of Drugs Used in the Treatment of Parkinson’s Disease

  2002influential citation
• Clinical–Pathological study of levodopa complications

  2002cites this paper
• Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature

  2001cites this paper
• Parkinson's disease: medical and surgical treatment.

  2001cites this paper
• The protective role of levodopa in the human substantia nigra.

  2001cites this paper
• Antiparkinsonian activity and dyskinesia risk of ropinirole and L‐DOPA combination therapy in drug naive MPTP‐lesioned common marmosets (Callithrix jacchus)

  2001cites this paper
• Motor fluctuations and dyskinesia in Parkinson's disease.

  2001cites this paper
• Parkinson’s disease: Initial treatment with levodopa or dopamine agonists

  2001cites this paper
• The spectrum of levodopa-induced dyskinesias.

  2000cites this paper
• Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.

  2000influential citation
• New Drugs for the Treatment of Parkinson's Disease

  2000cites this paper
• Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease

  2000cites this paper
• Is levodopa toxic?

  2000cites this paper
• Risk factors for levodopa-induced dyskinesias in Parkinson’s disease

  1999cites this paper
• Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells

  1999cites this paper
• Exogenous levodopa is not toxic to elderly subjects with non-parkinsonian movement disorders: further clinical evidence

  1999cites this paper
• Levodopa in Parkinson’s Disease

  1999cites this paper
• From off-period dystonia to peak-dose chorea. The clinical spectrum of varying subthalamic nucleus activity.

  1999cites this paper
• The initial treatment of Parkinson's disease should begin with levodopa

  1999cites this paper
• [Arguments in favor of the early treatment of Parkinson's disease with L-Dopa].

  1999cites this paper
• Immediate-release and controlled-release carbidopa/levodopa in PD

  1999cites this paper
• [Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease].

  1999cites this paper
• [Arguments in favor of early treatment of Parkinson's disease with dopaminergic agonists].

  1999cites this paper
• Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA.

  1999cites this paper
• Motor fluctuations in Parkinson's disease.

  1999cites this paper
• Acute interactions between L-DOPA and the neurotoxic effects of 1-methyl-4-phenylpyridinium or 6-hydroxydopamine in mice.

  1999cites this paper
• Parkinson's disease: therapeutic choices and timing decisions in patient management. Interview by Wayne Kuznar.

  1999cites this paper
• Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist.

  1999cites this paper
• New use for an old drug: amantadine benefits levodopa-induced dyskinesia.

  1998cites this paper
• Does timing and dosage of levodopa modify drug-induced dyskinesias and motor fluctuations? A retrospective analysis.

  1998cites this paper
• Does combined levodopa and bromocriptine therapy in Parkinson's disease prevent late motor complications?

  1998cites this paper
• Medical treatment of Parkinson’s disease

  1998cites this paper
• Is levodopa toxic to human substantia nigra?

  1998cites this paper
• Associative and limbic regions of monkey striatum express high levels of dopamine D3 receptors: effects of MPTP and dopamine agonist replacement therapies

  1998cites this paper
• Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia.

  1998cites this paper
• Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions

  1998cites this paper
• [Initial treatment of Parkinson's disease].

  1997cites this paper
• Parkinson's disease: prospects for improved drug therapy.

  1997cites this paper
• Absence of neurotoxicity of chronic L‐DOPA in 6‐hydroxydopaminelesioned rats

  1997cites this paper
• [Physiopathology of the dyskinesias induced by L-dopa].

  1997cites this paper
• Parkinson's Disease

  1997cites this paper
• Motor Complications of Chronic Levodopa Therapy in Parkinson's Disease

  1997cites this paper
• Levodopa-Induced Neurotoxicity

  1997cites this paper
• Neurobiology of L-DOPAergic systems.

  1996cites this paper
• Risk Factors for Peak Dose Dyskinesia in 100 Levodopa-treated Parkinsonian Patients

  1996cites this paper
• Controversies in the therapy of Parkinson's disease.

  1996cites this paper
• Drug management of Parkinson's disease.

  1996cites this paper
• Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa

  1996cites this paper
• Complications of disease and therapy: a comparison of younger and older patients with Parkinson's disease.

  1996cites this paper
• Treatment of early Parkinson's disease: are complicated strategies justified?

  1996cites this paper
• Is levodopa toxic?

  1996cites this paper
• Parkinson's disease: progression and mortality in the L-DOPA era.

  1996cites this paper
• Fluorodopa Positron Emission Tomography with an Inhibitor of Catechol-O-Methyltransferase: Effect of the Plasma 3-O-Methyldopa Fraction on Data Analysis

  1996cites this paper
• Early Detection of Parkinson’s Disease

  1996cites this paper
• Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group.

  1996cites this paper
• Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants.

  1995cites this paper
• Parkinson’s disease, dopamine and free radicals

  1995cites this paper
• Age at onset: the major determinant of outcome in Parkinson's disease

  1995cites this paper
• Perspective of neurochemistry in neurological disorders.

  1995cites this paper
• Possible neuroprotective therapy for Parkinson's disease.

  1995cites this paper
• Treatment of Parkinson's disease.

  1995cites this paper
• Tratamento da doença de Parkinson

  1995cites this paper
• Idiopathic Parkinson's disease: epidemiology, diagnosis and management.

  1995cites this paper
• [Treatment of Parkinson disease].

  1995cites this paper